AUCKLAND Wednesday, 24 September 2025 - Roche Products (New Zealand) Ltd today welcomed Pharmac’s decision to consult on proposed funding of four treatments that could transform care for thousands of ...

Ocrevus subcutaneous maintains consistent benefit-risk profile after two years -- New late-breaking data confirms Ocrevus ...

Are GLP-1 weight loss drugs the best we can do? Learn why some are pursuing alternatives to appetite suppression.

Hidradenitis suppurativa (HS) may affect 1 in 100 people. Lily is now speaking up so no one else has to suffer in silence.

Medically reviewed by Femi Aremu, PharmD Key Takeaways While both contain semaglutide, Wegovy is approved specifically for weight management, whereas Ozempic is approved for the treatment of type 2 ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option ...

This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults ...

Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

Eisai and Biogen have won FDA approval for a subcutaneous injection version of Leqembi that could help accelerate uptake of the Alzheimer's disease therapy. The green light for Leqembi Iqlik ...

Novo Nordisk has moved quickly to file for approval of a new, higher-dose version of its obesity therapy Wegovy as it tries to fend off a growing challenge in the market from arch-rival Eli Lilly.

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...